Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00095-5/abstract?utm_campaign=infocusalerts-oncology&utm_medium=email&dgcid=hubspot_email_infocusalerts-oncology_feature&_hsenc=p2ANqtz-_lY2oKxwKz_qclACjSFXhwixdywkDRM24azOZUj5JNh-n6GeSKifYmIvfHuyuFG3ILOxI31GUzQu6nzonngayTzDEn8w&_hsmi=319552803&utm_content=319101856&utm_source=hs_email